Tele-HOPE: A Telehealth Pharmacist Opioid Patient Education Pilot Study

NCT07737314 | Not Yet Recruiting

• 4 other identifiers: RG1126526NCI-2026-050930021316P30CA015704
• Study Type: interventional
• Target: 50
• Locations: 1 country
• Sites: 1

Brief Summary

This clinical trial will evaluate the feasibility, acceptability, and potential efficacy of a palliative care pharmacist-led group telehealth opioid education session for palliative care patients prescribed opioids for cancer-related pain. While opioids are commonly used in palliative care settings to manage cancer-related pain, their significant side effects, complicated administration requirements, and concerns about addiction can make it challenging for patients to use opioids safely and effectively. Some patients may even avoid opioids altogether because of these concerns, even when opioids are clinically indicated, leading to poor symptom control. To address these challenges, a telehealth education session was developed as a clinical initiative by a palliative care pharmacist, addressing safe and effective opioid management. Educational priorities and session content were informed by a survey of interdisciplinary palliative care clinicians that identified barriers and facilitators to opioid education and key patient educational needs. Patients scheduled to attend a pharmacist-led group telehealth opioid education session who enroll in the study will complete a survey before the session and another survey afterward. This study will assess the feasibility and acceptability of delivering the intervention, as well as its preliminary effects on opioid knowledge and self-efficacy. If feasible and acceptable, this pharmacist-led telehealth education model could represent a scalable strategy to improve opioid management for patients with cancer-related pain.

Conditions

Hematopoietic and Lymphatic System Neoplasm; Malignant Solid Neoplasm

Outcome Measures

Primary Outcomes (2)

• Percentage of referred patients who attend pharmacist education session (Feasibility)

  Feasibility of the pharmacist education session will be interpreted as an overall session attendance-to-referral rate ≥ 50%.

  Up to 6 months

• Participant score on the "general acceptability" item of the Theoretical Framework of Acceptability questionnaire

  Assessed on post-session surveys, delivered within 7 days after session attendance, with up to one month of follow-up to encourage survey completion. Acceptability of the pharmacist education session will be interpreted as \> 70% respondents rating the sessions as ≥ 4/5 (i.e. "acceptable" or "completely acceptable") on the "general acceptability" item of the Theoretical Framework of Acceptability scale (5 point Likert scale), assessed on the post-session survey.

  Up to 1 month post-session

Study Arms (1)

Supportive care (pharmacist-led opioid education session)

EXPERIMENTAL

Patients scheduled to attend a pharmacist-led group telehealth opioid education session who enroll in the study will complete a survey before the session and another survey afterward. After attending the pharmacist education session, patients will receive a patient education handout summarizing the educational content.

Other: Survey Administration; Other: Electronic Health Record Review

Interventions

Survey Administration OTHER

Ancillary studies - pre- and post-session surveys to assess opioid knowledge and self-efficacy, and post-session to assess session acceptability

Supportive care (pharmacist-led opioid education session)

Electronic Health Record Review OTHER

Ancillary studies

Supportive care (pharmacist-led opioid education session)

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Age ≥ 18 years, consistent with the population of patients treated at Fred Hutch Cancer Center
• A cancer diagnosis
• Established care in the Fred Hutch Palliative Care Clinic (≥ 1 visit with a Fred Hutch palliative care physician or advanced practice provider within the past 12 months)
• Prescribed opioids, defined as either ≥ 1 opioid prescription within the past 6 months documented in the Washington Prescription Drug Monitoring Program (PDMP), or a new opioid prescription initiated by the referring palliative care provider at the time of referral
• Ability to understand and willingness to agree to an electronic consent document
• Enrolled in MyChart and ability to participate in a telehealth video visit

You may not qualify if:

• Patients who prefer a language other than English for healthcare, as the session will be conducted live and cannot currently be offered in other languages

Sponsors & Collaborators

• Fred Hutchinson Cancer Center: lead
• National Cancer Institute (NCI): collaborator

Study Sites (1)

Fred Hutch/University of Washington Cancer Consortium

Seattle, Washington, 98109, United States

Location

Study Officials

• Nicole Dussault, MD, MS

  Fred Hutch/University of Washington Cancer Consortium

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Sheri Ballard

CONTACT

206-667-4222; sballard@fredhutch.org

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: NA
• Masking: NONE
• Purpose: SUPPORTIVE CARE
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: July 27, 2026
• First Posted: July 30, 2026
• Study Start (Estimated): November 1, 2026
• Primary Completion (Estimated): July 31, 2027
• Study Completion (Estimated): August 31, 2027
• Last Updated: July 30, 2026

Record last verified: 2026-07

Data Sharing

• IPD Sharing: Will share
• Shared Documents: STUDY PROTOCOL, SAP, ICF
• Time Frame: Data will be made available no later than the time of publication of the primary study results or within 12 months of completion of the project period, whichever occurs first.
• Access Criteria: Shared data will be made available with minimal access restrictions, consistent with protecting participant privacy and honoring informed consent. Data will be licensed to permit reuse for non-commercial research purposes, including secondary analyses, methodologic studies, and meta-analyses, with appropriate citation of the original dataset and investigators. Users of the data will be required to acknowledge the data source in publications and presentations. No attempt will be made to re-identify study participants, and no data will be shared that could reasonably place participants at risk of deductive disclosure.

Locations

US (1)